Live Breaking News & Updates on குழு மீடியா தொடர்பு

Stay updated with breaking news from குழு மீடியா தொடர்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Helsinn appoints Mary Lynne Hedley to Board of Directors


Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
| Source:
Helsinn Healthcare S.A.
Helsinn Healthcare S.A.
20
21 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021.
Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that chan ....

United States , Paola Bonvicini , Riccardo Braglia , Mary Lynne Hedley , Purdue University , Helsinn Group Vice , Swiss Pharma Company , Abraxis Bioscience , Harvard University , Helsinn Group Media Contact , B Future Health Fund , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Helsinn Investment Fund , Eisai Inc , China Helsinn Pharmaceuticals , Ut Southwestern Medical Center , Group Head Of Communication , Centessa Pharmaceuticals , Business Development , Chief Operating Officer , Executive Vice President , Medical Affairs , Cellular Immunology , Medical Center , Youville Assisted Living Communities ,

Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors


Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors
20
21 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021.
Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that changed the treatment paradigm for women diagnosed with ovarian cancer. The company was acquired by GlaxoSm ....

United States , Paola Bonvicini , Riccardo Braglia , Mary Lynne Hedley , Purdue University , Helsinn Group Vice , Swiss Pharma Company , Abraxis Bioscience , Harvard University , Helsinn Group Media Contact , B Future Health Fund , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Helsinn Investment Fund , Eisai Inc , China Helsinn Pharmaceuticals , Ut Southwestern Medical Center , Group Head Of Communication , Centessa Pharmaceuticals , Business Development , Chief Operating Officer , Executive Vice President , Medical Affairs , Cellular Immunology , Medical Center , Youville Assisted Living Communities ,